Clinical Trial: Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07686367) titled 'Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers' on July 03.

Brief Summary: This phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and myxoid/round cell liposarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Brenetafusp (IMC-F106C) is in a new class of immunotherapy called immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC). Brenetafusp (IMC-F106C), may induce changes in ...